Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fujue Wang

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Journal of Cancer Research and Clinical Oncology|May 23, 2023
Correction: Mitochondrial dysfunction and drug targets in multiple myelomaYushan Cui, Fujue Wang, Baijun Fang
Journal of Cancer Research and Clinical Oncology|March 17, 2023
Mitochondrial dysfunction and drug targets in multiple myelomaYushan Cui, Fujue Wang, Baijun Fang
Leukemia Research Reports|May 31, 2022
Microtransplantation for myeloid sarcoma: Two case reportsXue Zhang, Shuoting Wang, Fujue Wang, et al.
Journal of Cancer|May 6, 2020
Aberrant LncRNA Expression in LeukemiaJie Gao, Fujue Wang, Pengqiang Wu, et al.
Clinical and Experimental Medicine|March 19, 2026
Investigation of the expression and potential mechanistic role of BYSL in acute myeloid leukemiaJie Gao, Fujue Wang, Yingying Chen, et al.
Oncotarget|November 5, 2017
Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4Tao Jiang, Fujue Wang, Lianjie Hu, et al.
Oncotarget|May 17, 2018
Correction: Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4Tao Jiang, Fujue Wang, Lianjie Hu, et al.
American Journal of Translational Research|April 8, 2024
Erratum: CD31 promotes diffuse large B-cell lymphoma metastasis by upregulating OPN through the AKT pathway and inhibiting CD8+ T cells through the mTOR pathwayZhengchang He, Shaoxian Shen, Yuyao Yi, et al.
Journal of Orthopaedic Surgery and Research|May 25, 2023
CPEB2 enhances cell growth and angiogenesis by upregulating ARPC5 mRNA stability in multiple myelomaPiaorong Zeng, Fujue Wang, Xingxing Long, et al.
Frontiers in Pharmacology|February 8, 2024
Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)Yiwen Bao, Jiaju Chen, Luting Duan, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Journal of Cancer Research and Clinical Oncology|May 23, 2023
Correction: Mitochondrial dysfunction and drug targets in multiple myelomaYushan Cui, Fujue Wang, Baijun Fang
Journal of Cancer Research and Clinical Oncology|March 17, 2023
Mitochondrial dysfunction and drug targets in multiple myelomaYushan Cui, Fujue Wang, Baijun Fang
Leukemia Research Reports|May 31, 2022
Microtransplantation for myeloid sarcoma: Two case reportsXue Zhang, Shuoting Wang, Fujue Wang, et al.
Journal of Cancer|May 6, 2020
Aberrant LncRNA Expression in LeukemiaJie Gao, Fujue Wang, Pengqiang Wu, et al.
Clinical and Experimental Medicine|March 19, 2026
Investigation of the expression and potential mechanistic role of BYSL in acute myeloid leukemiaJie Gao, Fujue Wang, Yingying Chen, et al.
Oncotarget|November 5, 2017
Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4Tao Jiang, Fujue Wang, Lianjie Hu, et al.
Oncotarget|May 17, 2018
Correction: Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4Tao Jiang, Fujue Wang, Lianjie Hu, et al.
American Journal of Translational Research|April 8, 2024
Erratum: CD31 promotes diffuse large B-cell lymphoma metastasis by upregulating OPN through the AKT pathway and inhibiting CD8+ T cells through the mTOR pathwayZhengchang He, Shaoxian Shen, Yuyao Yi, et al.
Journal of Orthopaedic Surgery and Research|May 25, 2023
CPEB2 enhances cell growth and angiogenesis by upregulating ARPC5 mRNA stability in multiple myelomaPiaorong Zeng, Fujue Wang, Xingxing Long, et al.
Frontiers in Pharmacology|February 8, 2024
Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)Yiwen Bao, Jiaju Chen, Luting Duan, et al.
Pageof 3